Understanding cancer through genomic profiling and analytics
Official title: Implementation of Comprehensive Molecular Profiling and Deep Clinical Annotation of Electronic Health Records in Participants Diagnosed With or at Risk of Developing Cancer (ASAP Study)
Run by Avera McKennan Hospital & University Health Center · NCT05142033 · Data updated 2026-11-12
This study is trying to understand the genetic features of different types of cancer in people from a community healthcare system to improve screening and treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 25000 (estimated) |
| Sponsor | Avera McKennan Hospital & University Health Center Academic / other |
| Locations | 6 sites (Marshall, Minnesota and 5 other locations) |
| Status | Recruiting |
| Started | November 1, 2021 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | October 28, 2026 |
| Trial ID | NCT05142033 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older who are undergoing evaluation for a premalignant condition or have a cancer diagnosis.
✕Probably not a fit
Patients who are unable to understand the consent process or have psychiatric conditions that prevent them from participating may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the molecular characteristics of cancer in participants from a large community-based healthcare system. By utilizing comprehensive genomic profiling and proteomics, the study seeks to identify genomic drivers of both premalignant and malignant conditions across various cancer types. Participants will undergo somatic tumor testing and hereditary cancer testing to enhance screening, prognosis, and therapeutic strategies. The findings may also have implications for genetic counseling and cascade testing for families.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection and personalized treatment strategies for cancer patients.
How similar studies have gone: Other studies utilizing genomic profiling in cancer diagnosis have shown promising results, indicating that this approach is supported by prior successes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Must be at least 18 years of age * Must be undergoing a workup or being followed for a premalignant condition or have a diagnosis of cancer * Must voluntarily sign and understand the most current IRB-approved consent form prior to study participation Exclusion Criteria: * Participants incapable of understanding the items listed in the consent form and process * Participants with a history of or known psychiatric illness deemed unable to consent or adhere to study requirements
Where it's running
-
Avera Cancer Institute - Marshall
Marshall, Minnesota, United States Recruiting -
Avera Cancer Institute - Aberdeen
Aberdeen, South Dakota, United States Recruiting -
Avera Cancer Institute - Mitchell
Mitchell, South Dakota, United States Recruiting -
Avera Cancer Institute - Pierre
Pierre, South Dakota, United States Recruiting -
Avera Cancer Institute
Sioux Falls, South Dakota, United States Recruiting -
Avera Cancer Institute - Yankton
Yankton, South Dakota, United States Recruiting
Study contacts
- Principal investigator: Rachel Elsey, PharmD — Avera Cancer Institute
- Study coordinator: Rachel Elsey, PharmD
- Email: Rachel.Elsey@avera.org
- Phone: 605-322-3225
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Virtual exercise program to preserve function and prevent disability during chemotherapy
This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.
-
A resource for collecting cancer data and biospecimens
This study is creating a resource to collect health information and samples from cancer patients and healthy individuals to help improve cancer prevention and treatment strategies.
-
Riluzole to prevent thinking and memory problems during chemotherapy
This pilot trial tests whether riluzole can prevent thinking and memory problems in adults with cancer receiving anthracycline- or platinum-based chemotherapy.
-
EXoPERT EMERALD: a blood test using AI on extracellular vesicles to detect early lung, breast, colorectal, pancreatic, and ovarian cancers.
This test tries to detect early lung, breast, colorectal, pancreatic, and ovarian cancers from a single blood sample by using AI to read Raman spectroscopy patterns of tiny particles called extracellular vesicles.
-
Florida ASCENT Program
This project will test whether combining the MyCarePulse EHR platform with ASCENT patient navigators helps adults with recent cancer diagnoses in Florida improve food security, diet quality, and confidence in healthy eating compared with standard care.
-
Using brodalumab to treat immune-related side effects from cancer therapy
This study is testing if brodalumab can help cancer patients who are having immune-related side effects from their immunotherapy treatment feel better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.